The global urinary tract infection (UTI) testing market was valued at USD 602.7 million in 2022 and is expected to reach USD 812.0 million by 2030, registering a CAGR of 4.4% from 2023 to 2030. Market growth is primarily driven by the rising incidence of urinary tract infections worldwide, which continue to represent a significant public health concern across both developed and developing regions. The increasing patient pool, coupled with the growing need for timely and accurate diagnosis to prevent complications, is supporting sustained demand for UTI testing solutions.

Urinary tract infections are among the most common bacterial infections, particularly affecting women. Research indicates that nearly one in five adult women experiences a UTI at some point in her lifetime. In the U.S. alone, approximately 25%–40% of women between the ages of 20 and 40 have reported suffering from UTIs, underscoring the widespread prevalence of the condition. Annually, more than 6 million UTI-related physician visits are recorded in the U.S., with nearly 20% of these cases requiring emergency department care. Women are significantly more susceptible to UTIs than men due to anatomical and hormonal factors, and the incidence rate tends to rise with advancing age. Postmenopausal women are particularly vulnerable, as hormonal changes alter vaginal flora, creating favorable conditions for pathogenic bacterial growth. According to Cell Reports Medicine (2022), nearly 50% of UTIs in postmenopausal women progress to recurrent infections, which may persist for years, adversely affecting both physical health and mental well-being. If left untreated or inadequately managed, UTIs can escalate into severe complications such as urosepsis, which can be life-threatening.

Technological advancements in diagnostics are playing a crucial role in expanding market adoption. The introduction of portable handheld diagnostic devices, along with at-home sample collection and self-testing kits, has significantly improved accessibility and convenience for patients. For example, in May 2020, Healthy.io Ltd. launched a home-based UTI test kit in the UK, enabling patients to conduct testing without visiting healthcare facilities. Point-of-care (PoC) testing is emerging as a major growth area, as it allows rapid diagnosis and early treatment, reducing the burden on hospitals and laboratories. Increased investment by market players in PoC diagnostics is expected to accelerate innovation further. Additionally, researchers are developing next-generation diagnostic solutions that leverage digital technologies. In January 2020, engineers at the University of Bath introduced a smartphone-based UTI test capable of detecting E. coli in urine samples in under 25 minutes, highlighting the potential for fast, low-cost, and highly accessible diagnostic tools to transform UTI testing.

Key Market Trends & Insights:

• North America dominated the urinary tract infection testing market in 2022, accounting for a revenue share of 34.0%. This dominance is attributed to the high disease burden, well-established healthcare infrastructure, increased healthcare spending, rapid adoption of advanced diagnostic technologies, supportive government initiatives, growing patient awareness, and the strong presence of leading market players.
• In contrast, the Asia Pacific region is expected to witness the fastest CAGR of 5.2% during the forecast period. This accelerated growth is driven by the rising incidence of UTIs, expanding healthcare access, improving diagnostic capabilities, and a rapidly growing geriatric population, which is more susceptible to urinary infections.
• By type, the cystitis segment held the largest revenue share of 41.4% in 2022, reflecting its high prevalence among UTI cases. Meanwhile, the pyelonephritis segment is anticipated to grow at the fastest CAGR of 4.8% over the forecast period, supported by the increasing prevalence of kidney-related infections and the need for more accurate diagnostic solutions.
• In terms of end use, reference laboratories accounted for the largest revenue share of approximately 26.7% in 2022, driven by continuous efforts to improve diagnostic accuracy and patient outcomes through advanced laboratory services. The urogynecologists segment is expected to register the fastest CAGR of 5.2%, as specialized care and targeted diagnostic approaches gain prominence in managing recurrent and complex UTI cases.

Order a free sample PDF of the Urinary Tract Infection Testing Market Intelligence Study, published by Grand View Research.

Market Size & Forecast:

• 2022 Market Size: USD 602.7 Million
• 2030 Projected Market Size: USD 812.0 Million
• CAGR (2023-2030): 4.4%
• North America: Largest market in 2022
• Asia Pacific: Fastest growing market

Key Companies & Market Share Insights:

Leading players in the global urinary tract infection testing market are actively pursuing growth strategies such as product launches, mergers and acquisitions, and technological collaborations to strengthen their market position. In December 2022, Thermo Fisher Scientific introduced the TrueMark Infectious Disease Research Panels, designed to enable rapid and precise detection of microorganisms responsible for urinary, gastrointestinal, respiratory, vaginal, and sexually transmitted infections. In September 2022, Sysmex Corporation launched the UF-1500, a fully automated urine particle analyzer that enhances urine sediment testing efficiency and accuracy. Similarly, in May 2022, Vela Diagnostics unveiled the AMR PCR Test along with PathoKey MP UTI ID, facilitating the detection of UTI pathogens and antimicrobial resistance genes.

Strategic acquisitions and home-based diagnostic innovations are further shaping the competitive landscape. In December 2021, BD (Becton, Dickinson, and Company) completed the acquisition of Scanwell Health Inc., a developer of smartphone-enabled at-home diagnostic kits. In July 2020, Uqora, Inc., a urinary health biotechnology company under Pharmavite, LLC, launched a comprehensive UTI diagnostic and management kit featuring the Clarify rapid diagnostic device suitable for both point-of-care and homecare settings. Likewise, Healthy.io Ltd.’s launch of a rapid at-home UTI test kit in May 2020 exemplifies the growing shift toward decentralized and patient-centric diagnostic solutions.

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion:

In conclusion, the urinary tract infection testing market is experiencing steady growth due to the rising prevalence of UTIs, particularly among women and the aging population. Advancements in diagnostic technologies, including point-of-care and at-home testing solutions, are improving early detection and patient convenience. Strong investments by key market players in innovative and automated testing platforms are further enhancing diagnostic accuracy and efficiency. Together, these factors are expected to support sustained market expansion throughout the forecast period.